# Sources — Evel Knievel

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 4, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Stacy M (The Associated Press). “Evel Knievel, iconic daredevil, dies at 69 of natural causes,” *Lawrence Journal-World*, December 1, 2007. Obituary: supports his birth as Robert Craig Knievel in Butte, Montana, on October 17, 1938, and his upbringing by his grandparents; the start of his career in 1965; the Caesars Palace crash in 1968 that left him in a coma; the 1974 Snake River Canyon attempt; the concussion and two broken arms in the 1976 Chicago jump and his retirement from major jumps; “nearly 40 broken bones before he retired in 1980”; that he “had been in failing health for years, suffering from diabetes and idiopathic pulmonary fibrosis”; the 1999 liver transplant “after nearly dying of hepatitis C, likely contracted through a blood transfusion after one of his many spills”; two recent strokes; and his death of natural causes after trouble breathing at his Clearwater condominium. https://www2.ljworld.com/news/2007/dec/01/evel_knievel_iconic_daredevil_dies_69_natural_caus/
2. ESPN.com news services. “Evel Knievel dies at 69; had long been in failing health,” November 30, 2007. Supports the diabetes and pulmonary fibrosis, the hepatitis C “likely contracted through a blood transfusion after one of his bone-shattering spills,” the 1999 transplant, “two strokes in recent years,” the month-long coma after the Caesars Palace crash, and the pelvis broken at Wembley Stadium. https://www.espn.co.uk/espn/news/story?id=3135532
3. Reuters. “Daredevil Evel Knievel dies after long illness,” *Mail & Guardian*, December 1, 2007. Supports that his final years were plagued by pain from his accidents and by pulmonary fibrosis; his own words in a *USA Today* interview published early in 2007, where he was described as reliant on an oxygen tank and an implanted drug pump to relieve his pain; almost a month in a coma in 1968; and that he “did not quit drinking until undergoing a liver transplant in 1999.” https://mg.co.za/2007-12-01-daredevil-evel-knievel-dies-after-long-illness/
4. Guinness World Records. “Most broken bones in a lifetime.” Supports the record title and the figure of 433 bone fractures by the end of 1975, with the 1976 concussion and two broken arms and his retirement from major performances. https://www.guinnessworldrecords.com/world-records/most-broken-bones-in-a-lifetime
5. Selbie J. “Stunt legend Evel Knievel’s unfortunate record after he broke his bones hundreds of times,” Guinness World Records, November 28, 2025. Supports the 433 fractures by the end of 1975, a skull fracture in the Caesars Palace crash, and his death on November 30, 2007. https://www.guinnessworldrecords.com/news/2025/11/stunt-legend-evel-knievels-unfortunate-record-after-he-broke-his-bones-hundreds-of-times
6. The Associated Press. “Motorcycle daredevil Evel Knievel dies at 69,” *Deseret News*, November 30, 2007. Supports the wording “diabetes and idiopathic pulmonary fibrosis” and the transfusion-acquired hepatitis C and 1999 transplant. https://www.deseret.com/2007/11/30/20056581/motorcycle-daredevil-evel-knievel-dies-at-69/
7. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.

## Clinical guidance

1. AASLD-IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (updated December 19, 2023): eligibility (Child-Pugh A, no prior treatment, eGFR 30 or more, HBsAg negative, no HCC or transplant), cirrhosis presumed with FIB-4 above 3.25 or elastography above 12.5 kPa, ultrasound within six months, CBC, INR, hepatic panel and eGFR within three months, HBsAg, HIV and genotype before sofosbuvir-velpatasvir, drug interaction review, sofosbuvir-velpatasvir 12 weeks or glecaprevir-pibrentasvir 8 weeks, hypoglycemia warning on diabetes medicines, HCV RNA and hepatic panel 12 or more weeks after treatment, HCC ultrasound with or without AFP every six months after cure, and alcohol avoidance. https://www.hcvguidelines.org/guidance/simplified-hcv-treatment-algorithm-for-treatment-naive-adults-with-compensated-cirrhosis/ ; monitoring section: https://www.hcvguidelines.org/guidance/monitoring-patients-who-are-starting-hcv-treatment-are-on-treatment-or-have-completed-therapy/
2. EPCLUSA (sofosbuvir and velpatasvir) prescribing information, DailyMed: boxed warning for hepatitis B reactivation; 12 weeks for compensated cirrhosis; proton pump inhibitors not recommended (if necessary, with food 4 hours before omeprazole 20 mg); H2-receptor antagonists with or 12 hours apart, up to famotidine 40 mg twice daily; rosuvastatin no more than 10 mg and monitoring with atorvastatin; amiodarone not recommended; hypoglycemia in diabetic patients. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f30631a-ee3b-4cfe-866b-964df3f0a44f
3. Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology* 2023;78(6):1922-1965 (PMID 37199193). https://pubmed.ncbi.nlm.nih.gov/37199193/
4. de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. *J Hepatol* 2022;76(4):959-974 (PMID 35120736). https://pubmed.ncbi.nlm.nih.gov/35120736/ ; Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. *Hepatology* 2024;79(5):1180-1211 (PMID 37870298). https://pubmed.ncbi.nlm.nih.gov/37870298/
5. Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. *Hepatology* 2021;74(2):1014-1048 (PMID 33942342). https://pubmed.ncbi.nlm.nih.gov/33942342/
6. Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. *Hepatology* 2020;71(1):306-333 (PMID 31314133). https://pubmed.ncbi.nlm.nih.gov/31314133/ ; USPSTF, Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018).
7. Rakoski M, et al. Pain management in patients with cirrhosis. *Clin Liver Dis (Hoboken)* 2018;11(6):135-140 (PMID 30992804). https://pubmed.ncbi.nlm.nih.gov/30992804/ ; Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain, 2022. *MMWR Recomm Rep* 2022;71(3):1-95 (PMID 36327391). https://pubmed.ncbi.nlm.nih.gov/36327391/
8. American Diabetes Association. Standards of Care in Diabetes-2026, sections 4 (Comprehensive Medical Evaluation and Assessment of Comorbidities; PMID 41358897) and 6 (Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises; PMID 41358894). https://pubmed.ncbi.nlm.nih.gov/41358897/
9. Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2012;97(6):1802-1822 (PMID 22675062). https://pubmed.ncbi.nlm.nih.gov/22675062/
10. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), diabetes type 2 monograph (A1c every three months when not at goal, CGM review, yearly urine albumin, eye and foot examinations, lipids on a statin, vitamin B12 on long-term metformin), osteoporosis monograph (secondary-cause work-up, calcium before each zoledronic acid dose, DXA every one to three years on therapy, fall-risk screening) and depression monograph. The CMID has no liver disease monograph, so the AASLD, AASLD-IDSA and Baveno guidance govern the liver care. https://patrickrutledge.github.io/topthirty/
11. USPSTF: hepatitis C screening (2020), A and B recommendations, colorectal cancer (2021), prostate cancer (2018) and depression (2023); CDC Adult Immunization Schedule by Medical Condition and Other Indication; Medicare Preventive Services reference (Aether Forge, 2026). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations

## Editorial resolutions

- **Recent-death rule.** Knievel died in 2007, so the rule applies. The case uses only what was reported in obituaries and record-keeper accounts (the Associated Press, ESPN, Reuters, the *Deseret News* and Guinness World Records) and his own words in a newspaper interview quoted by Reuters. No sick visit is added. His death is recorded once (CLM-0009), in plain words. Two claims are marked sensitive: the Reuters report that he did not stop drinking until his 1999 transplant (CLM-0006) and the implanted drug pump for pain in his last year (CLM-0008).
- **Alcohol.** The roster lists “alcohol use disorder.” No source fetched gives that diagnosis, so none is made: there is no F10 code, and alcohol appears only in the social history, as AUDIT-C scores and as counseling, all synthetic and anchored to the obituary report. The modern episode has him cut down after counseling and stop when treatment starts; this is a synthetic course and implies nothing about his real drinking. No safety assessment is required (no behavioral-health code; PHQ-9 at most 6; PHQ-2 at most 1).
- **What is not public.** When his hepatitis C was diagnosed, the stage of his liver disease before the transplant, and any treatment he had were not made public; one secondary page dates the diagnosis to 1993, but it is not a reliable source and is not used. Every clinical detail in the modern episode (the presenting tests, genotype 1a, the viral load, liver stiffness, Child-Pugh and MELD-Na, carvedilol, sofosbuvir-velpatasvir and cure, osteoporosis, all values) is synthetic. The modern course ends in cure with compensated cirrhosis, as current treatment allows; it does not describe his real course, in which he needed a liver transplant three years after the true-frame index date.
- **Fractures.** CLM-0004 records the conflict: Guinness World Records lists 433 bone fractures by the end of 1975 under “most broken bones in a lifetime,” while the Associated Press obituary says nearly 40 broken bones before he retired in 1980. The claim is graded D with certainty “disputed,” and the modern episode says “dozens of fractures.” Other counts reported on Wikipedia, including his own lower estimate, are not cited.
- **Conflicts and gaps.** (1) The Caesars Palace crash is dated 1968 in the wire obituaries; the jump is usually dated to New Year’s Eve 1967, and later accounts dispute the month-long coma; CLM-0002 is graded probable and uses the obituaries’ year. (2) Cause of death: the roster says pulmonary fibrosis caused his death; the obituaries fetched report natural causes after years of diabetes and pulmonary fibrosis, so CLM-0009 states that. (3) The year of the pulmonary fibrosis diagnosis (2005 on Wikipedia, without a fetched source) and the dates of the two strokes are not stated; both conditions came after the index age and are not used in the modern episode. (4) The liver transplant hospital and month are not stated (secondary sources not used). (5) *The New York Times* obituary, Britannica and Smithsonian pages returned access errors and are not cited. (6) Hepatitis C is described as “likely contracted through a blood transfusion”; the modern episode treats transfusion before 1992 as the likely source, as the obituaries do.
- **Left out.** His 1977 assault conviction is not medical and is left out. The lawsuit, finances and family history reported in the obituaries are left out. No relative is named; the sons and granddaughter quoted in the obituaries have no role, and no health fact, statement or decision is attributed to any relative. The modern family history is left empty. The roster’s “PTSD from career injuries” has no source and is not used.
- **Alias.** “Robert Craig Knievel” is used as the alias; it appears in no other record. “Bob” and “Robert” alone are not used.
- **Index age and dates.** The index visit on January 12, 2026 maps to January 12, 1996, when he was 57, three years before the 1999 transplant. The synthetic date of birth is October 17, 1968 (shift 30 years). The chronic-care visits on January 26, February 23, May 18 and August 17, 2026 and the preventive visit on September 21, 2026 (age 57, so a periodic adult preventive visit) map to the same days of 1996, within his lifetime and before the transplant. The presenting-problem pattern is used: raised transaminases with low platelets (R74.01) are a resolved problem when hepatitis C with cirrhosis is diagnosed at the consultation. The claims about the transplant, drinking until the transplant, his last years and his death are linked to timeline events after the index date, so the intake documents do not show them.
- **Diabetes and pain at the index age.** His diabetes and chronic pain are documented only for his last years. Placing type 2 diabetes on metformin and chronic pain from old fractures at 57 is a synthetic choice that serves the teaching objective; both problems are linked to the documented claims and marked synthetic.
- **Synthetic clinical picture and teaching points.** Cirrhosis is diagnosed without biopsy (FIB-4 4.94, liver stiffness 26.8 kPa, nodular liver, splenomegaly, platelets 118). Sofosbuvir-velpatasvir was chosen over glecaprevir-pibrentasvir because the latter should not be given with atorvastatin; the proton pump inhibitor is stopped. Liver stiffness of 25 kPa or more establishes clinically significant portal hypertension under Baveno VII, so carvedilol is started and screening endoscopy is not done; this differs from the endoscopic surveillance named on the AASLD-IDSA page and follows the newer Baveno VII and AASLD 2024 portal hypertension guidance. Transplant evaluation is not indicated (compensated; MELD-Na 8, then 6). The A1c reads below the glucose management indicator, as it can in cirrhosis, so a continuous glucose monitor guides diabetes care. Osteoporosis is treated with zoledronic acid rather than an oral bisphosphonate because of portal hypertension. Pain care avoids oral NSAIDs and opioids. Qualitative results (serology, genotype, ultrasound, elastography details, DXA, retinal examination) appear in procedure and note text; liver stiffness and HCV RNA are coded. Height (178 cm) and weights are synthetic.
- **Preventive visit.** A periodic adult preventive visit at 57 (CPT 99396 with 99497 in plain text), five weeks after the test of cure. Judgment calls: colonoscopy ordered (never screened); PSA after shared decision-making; lung cancer screening not indicated (synthetic never-smoker); influenza, PCV20, recombinant zoster dose 1 and Tdap given; COVID-19 vaccine due at the pharmacy (no product code recorded). Advance care planning records only his general preferences and an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (the hepatology consultation day, day 1 of treatment, the end of treatment, and the test of cure with six-month surveillance) are documented as focused visits on the AASLD-IDSA HCV guidance and the sofosbuvir-velpatasvir label, the AASLD 2023 HCC guidance, Baveno VII and the AASLD portal hypertension and ascites guidance, the AASLD alcohol guidance, the cirrhosis pain review and CDC opioid guideline, the ADA Standards of Care, the Endocrine Society guideline and the CMID diabetes, osteoporosis and depression monographs. Two deviations are recorded instead of invented results: (1) the yearly diabetic eye examination was referred at the consultation visit but never booked because the referral was sent without an appointment request; it was booked at the end of treatment and done the next month (no retinopathy); (2) the six-month surveillance ultrasound was done about three weeks late because the recall was set from the hepatology visit and then held for the test of cure; no lesion was found, and the recall is now set from each scan date. Synthetic findings introduced: vitamin D deficiency (resolved with replacement), osteoporosis on DXA, and an A1c lower than the glucose management indicator.
- **Consultation.** The hepatology referral, written at intake when only the raised liver tests and low platelets were known, and the consultation by Mei-Ling Okonkwo, MD (a fictional consultant), on the day of the two-week visit, are **S**. The consultant answers the five referral questions in line with what the record shows afterwards: chronic hepatitis C with compensated cirrhosis; sofosbuvir-velpatasvir for 12 weeks with the interaction check; carvedilol without screening endoscopy; six-monthly ultrasound with alpha-fetoprotein for life, hepatitis A and B vaccination and transplant referral criteria; and pain, diabetes and alcohol care adapted to cirrhosis, with a bone density scan.
